IL162236A0 - Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use - Google Patents

Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use

Info

Publication number: IL162236A0
Authority: IL; Israel
Prior art keywords: envelopeproteins; dagnostic; virus; therapeutic use; purified hepatitis
Prior art date: 2001-12-18

Application number

IL16223602A

Other languages

English (en)

Original Assignee

Innogenetics Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-18

Filing date

2002-12-18

Publication date

2005-11-20

2002-12-18 Application filed by Innogenetics Nv filed Critical Innogenetics Nv

2005-11-20 Publication of IL162236A0 publication Critical patent/IL162236A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL16223602A 2001-12-18 2002-12-18 Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use IL162236A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2051001A	2001-12-18	2001-12-18
US41835802P	2002-10-16	2002-10-16
PCT/EP2002/014480 WO2003051912A2 (en)	2001-12-18	2002-12-18	Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Publications (1)

Publication Number	Publication Date
IL162236A0 true IL162236A0 (en)	2005-11-20

Family

ID=26693530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16223602A IL162236A0 (en)	2001-12-18	2002-12-18	Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use

Country Status (12)

Country	Link
EP (1)	EP1461080A2 (xx)
JP (1)	JP2005516939A (xx)
KR (1)	KR20040076869A (xx)
CN (1)	CN1622828A (xx)
AU (1)	AU2002361160B2 (xx)
BR (1)	BR0215081A (xx)
CA (1)	CA2468690A1 (xx)
IL (1)	IL162236A0 (xx)
MX (1)	MXPA04005891A (xx)
NZ (1)	NZ533396A (xx)
RU (1)	RU2319505C2 (xx)
WO (1)	WO2003051912A2 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7108855B2 (en)	1998-06-24	2006-09-19	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7101561B2 (en)	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002086101A2 (en)	2001-04-24	2002-10-31	Innogenetics N.V.	Core-glycosylated hcv envelope proteins
FR2859221B1 (fr) *	2003-08-28	2005-10-14	Centre Nat Rech Scient	Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations
EP1574517A1 (en)	2004-03-09	2005-09-14	Innogenetics N.V.	HCV E1 comprising specific disulfide bridges
WO2006044923A2 (en) *	2004-10-18	2006-04-27	Globeimmune, Inc.	Yeast-based therapeutic for chronic hepatitis c infection
CN100365124C (zh) *	2005-10-27	2008-01-30	云南大学	一段丙型肝炎病毒特异性cDNA序列的应用
WO2009030872A1 (en) *	2007-09-07	2009-03-12	Mats Axel Atterdag Persson	Materials and methods for the treatment of hepatitis c
CN102112155B (zh)	2008-06-05	2016-08-10	埃博灵克斯股份有限公司	针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽
CN105061592A (zh)	2009-06-05	2015-11-18	埃博灵克斯股份有限公司	用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
US9644022B2 (en)	2009-11-30	2017-05-09	Ablynx N.V.	Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN103732250A (zh) *	2011-06-14	2014-04-16	全球免疫股份有限公司	基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
RU2570553C2 (ru) *	2013-11-20	2015-12-10	Федеральное бюджетное учреждение "Всероссийский научно-исследовательский институт лесоводства и механизации лесного хозяйства (ФБУ ВНИИЛМ)	Способ очистки вирусных полиэдров
CN104327170A (zh) *	2014-05-16	2015-02-04	中国疾病预防控制中心病毒病预防控制所	丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CA2961568A1 (en)	2014-09-17	2016-03-24	The University Of Iowa Research Foundation	Viral rna segments as immunomodulatory agents and vaccine components
JP7068284B2 (ja) *	2016-09-29	2022-05-16	マクファーレンバーネットインスティテュートフォーメディカルリサーチアンドパブリックヘルスリミテッド	アセンブルした糖タンパク質
US20220041650A1 (en) *	2018-12-03	2022-02-10	Duke University	Purification method for recombinant proteins and nanoparticles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0992580B1 (en) *	1993-11-04	2005-03-09	Innogenetics N.V.	Immunodominant human T-cell epitopes of Hepatitis C virus
ATE286067T1 (de) *	1998-06-24	2005-01-15	Innogenetics Nv	Hcv hüllproteine partikel : verwendung für therapeutische impfung

2002
- 2002-12-18 CN CNA028282027A patent/CN1622828A/zh active Pending
- 2002-12-18 WO PCT/EP2002/014480 patent/WO2003051912A2/en active IP Right Grant
- 2002-12-18 CA CA002468690A patent/CA2468690A1/en not_active Abandoned
- 2002-12-18 NZ NZ533396A patent/NZ533396A/en unknown
- 2002-12-18 RU RU2004116914/15A patent/RU2319505C2/ru not_active IP Right Cessation
- 2002-12-18 IL IL16223602A patent/IL162236A0/xx unknown
- 2002-12-18 BR BR0215081-6A patent/BR0215081A/pt not_active IP Right Cessation
- 2002-12-18 AU AU2002361160A patent/AU2002361160B2/en not_active Expired - Fee Related
- 2002-12-18 KR KR10-2004-7009720A patent/KR20040076869A/ko not_active Application Discontinuation
- 2002-12-18 EP EP02796675A patent/EP1461080A2/en not_active Withdrawn
- 2002-12-18 JP JP2003552792A patent/JP2005516939A/ja active Pending
2004
- 2004-06-16 MX MXPA04005891A patent/MXPA04005891A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2003051912A2 (en)	2003-06-26
MXPA04005891A (es)	2004-09-13
RU2319505C2 (ru)	2008-03-20
EP1461080A2 (en)	2004-09-29
AU2002361160A1 (en)	2003-06-30
WO2003051912A3 (en)	2004-03-04
KR20040076869A (ko)	2004-09-03
WO2003051912A9 (en)	2004-07-15
NZ533396A (en)	2005-04-29
BR0215081A (pt)	2004-10-19
CA2468690A1 (en)	2003-06-26
JP2005516939A (ja)	2005-06-09
RU2004116914A (ru)	2005-04-20
AU2002361160B2 (en)	2008-07-03
CN1622828A (zh)	2005-06-01

Publication	Publication Date	Title
SI1404347T1 (sl)	2006-04-30	4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c
HUP0400882A3 (en)	2011-01-28	Oncolytic virus therapy
IL165860A0 (en)	2006-01-15	Administration of therapeutic viruses
IL162236A0 (en)	2005-11-20	Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
EP1367060A4 (en)	2004-04-14	GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en)	2004-05-06	GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en)	2004-04-14	GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
AP2002002704A0 (en)	2002-12-31	Methods and compositions for treating hepatitis c virus
EP1569652A4 (en)	2008-07-02	NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS
AU5618501A (en)	2001-09-24	Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
IL157251A0 (en)	2004-02-19	Hepatitis b virus treatment
IL143798A0 (en)	2002-04-21	Hepatitis c virus ns3 protease
HK1050011A1 (zh)	2003-06-06	用levovirintm治療病毒性感染
GB0119025D0 (en)	2001-09-26	Compounds and their therapeutic use
IL151033A0 (en)	2003-04-10	Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AP2002002432A0 (en)	2002-03-31	Treatment of viral infections
IL151188A0 (en)	2003-04-10	Medicament for viral diseases
AU2002332613A1 (en)	2003-03-03	Compositions and therapeutic methods for viral infection
AU2001234596A1 (en)	2001-08-07	Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2002327531A1 (en)	2003-03-10	Therapeutic compositions and methods for treating viral infection
EP1363611A4 (en)	2004-08-11	RETINOID TREATMENT OF HEPATITIS
AU2003299493A8 (en)	2004-05-13	Compositions and methods for the treatment of hepatitis c virus infection
GB2376943B (en)	2005-03-16	Compounds and their therapeutic use
GB0112237D0 (en)	2001-07-11	Compounds and their therapeutic use
SI1436397T1 (sl)	2010-09-30	Cepivo proti virusu hepatitisa C